This report summarises phase 2 trial results of biologic lung volume reduction (BioLVR) for treatment of advanced homogeneous emphysema. BioLVR therapy was administered bronchoscopically to 25 patients with homogeneous emphysema in an open-labelled study. Eight patients received low dose (LD) treatment with 10 mL per site at eight subsegments; 17 received high dose (HD) treatment with 20 mL per site at eight subsegments VSports手机版. Safety was assessed in terms of medical complications during 6-month follow-up. Efficacy was assessed in terms of change from baseline in gas trapping, spirometry, diffusing capacity, exercise capacity, dyspnoea and health-related quality of life. There were no deaths or serious medical complications during the study. A statistically significant reduction in gas trapping was observed at 3-month follow-up among HD patients, but not LD patients. At 6 months, changes from baseline in forced expiratory volume in 1 s (-8. 0+/-13. 93% versus +13. 8+/-20. 26%), forced vital capacity (-3. 9+/-9. 41% versus +9. 0+/-13. 01%), residual volume/total lung capacity ratio (-1. 4+/-13. 82% versus -5. 4+/-12. 14%), dyspnoea scores (-0. 4+/-1. 27 versus -0. 8+/-0. 73 units) and St George's Respiratory Questionnaire total domain scores (-4. 9+/-8. 3 U versus -12. 2+/-12. 38 units) were better with HD than with LD therapy. BioLVR therapy with 20 mL per site at eight subsegmental sites may be a safe and effective therapy in patients with advanced homogeneous emphysema. .